These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
343 related articles for article (PubMed ID: 31448091)
1. Inflammation in atherosclerotic cardiovascular disease. Shah PK; Lecis D F1000Res; 2019; 8():. PubMed ID: 31448091 [TBL] [Abstract][Full Text] [Related]
2. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Ridker PM; Libby P; MacFadyen JG; Thuren T; Ballantyne C; Fonseca F; Koenig W; Shimokawa H; Everett BM; Glynn RJ Eur Heart J; 2018 Oct; 39(38):3499-3507. PubMed ID: 30165610 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial. Everett BM; MacFadyen JG; Thuren T; Libby P; Glynn RJ; Ridker PM J Am Coll Cardiol; 2020 Oct; 76(14):1660-1670. PubMed ID: 33004131 [TBL] [Abstract][Full Text] [Related]
4. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Ridker PM; Thuren T; Zalewski A; Libby P Am Heart J; 2011 Oct; 162(4):597-605. PubMed ID: 21982649 [TBL] [Abstract][Full Text] [Related]
5. Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis. Ridker PM Circ Res; 2019 Feb; 124(3):437-450. PubMed ID: 30702995 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease. Ridker PM; MacFadyen JG; Glynn RJ; Koenig W; Libby P; Everett BM; Lefkowitz M; Thuren T; Cornel JH J Am Coll Cardiol; 2018 May; 71(21):2405-2414. PubMed ID: 29793629 [TBL] [Abstract][Full Text] [Related]
8. [Inflammation and atherosclerosis – last piece of the puzzle has fallen into place]. Jonasson L; Hansson G Lakartidningen; 2017 Oct; 114():. PubMed ID: 29292899 [TBL] [Abstract][Full Text] [Related]
11. Canakinumab: Promises and Future in Cardiometabolic Diseases and Malignancy. Dhorepatil A; Ball S; Ghosh RK; Kondapaneni M; Lavie CJ Am J Med; 2019 Mar; 132(3):312-324. PubMed ID: 30832770 [TBL] [Abstract][Full Text] [Related]
12. The Role of Suppressing Inflammation in the Treatment of Atherosclerotic Cardiovascular Disease. Roman YM; Hernandez AV; White CM Ann Pharmacother; 2020 Oct; 54(10):1021-1029. PubMed ID: 32425120 [TBL] [Abstract][Full Text] [Related]
13. Targeting Inflammation and Immune System in Acute Myocardial Infarction. Alwi I Acta Med Indones; 2019 Oct; 51(4):287-289. PubMed ID: 32041910 [TBL] [Abstract][Full Text] [Related]
14. Atherosclerosis: perspectives of anti-inflammatory therapy. Nasonov EL; Popkova TV Ter Arkh; 2018 May; 90(5):4-12. PubMed ID: 30701884 [TBL] [Abstract][Full Text] [Related]
15. Clinician's Guide to Reducing Inflammation to Reduce Atherothrombotic Risk: JACC Review Topic of the Week. Ridker PM J Am Coll Cardiol; 2018 Dec; 72(25):3320-3331. PubMed ID: 30415883 [TBL] [Abstract][Full Text] [Related]
16. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis. Ridker PM; MacFadyen JG; Thuren T; Libby P Eur Heart J; 2020 Jun; 41(23):2153-2163. PubMed ID: 31504417 [TBL] [Abstract][Full Text] [Related]
17. A new strategy for the treatment of atherothrombosis - inhibition of inflammation. Slíva J; Charalambous C; Bultas J; Karetová D Physiol Res; 2019 Nov; 68(Suppl 1):S17-S30. PubMed ID: 31755287 [TBL] [Abstract][Full Text] [Related]
18. Canakinumab for secondary prevention of coronary artery disease. Ortega-Paz L; Capodanno D; Angiolillo DJ Future Cardiol; 2021 May; 17(3):427-442. PubMed ID: 33533289 [TBL] [Abstract][Full Text] [Related]